CD6-ALCAM Polymorphisms Potentially Modulate Psoriasis Risk and Outcomes

According to a study published in Human Immunology, polymorphisms of CD6-ALCAM axis genes may modulate psoriasis risk and outcomes.

Researchers aimed to investigate the potential association between polymorphisms in CD6 and ALCAM genes and susceptibility to psoriasis vulgaris (PsV), as well as their influence on disease severity measured by the Psoriasis Area and Severity Index (PASI). Additionally, the study examined the presence of HLA-C*06:02, a known psoriasis risk factor.

Two hundred and seventy-three patients with PsV and 256 blood donors without dermatoses were included. Genotyping of CD6 (rs17824933C>G, rs11230563C>T, rs12360861G>A) and ALCAM (rs6437585C>T, rs11559013G>A) polymorphisms was performed using the allelic discrimination method.

The study revealed an association between the rs17824933G allele of CD6 and increased psoriasis risk in individuals with the HLA-C*06:02 genotype. Furthermore, a difference in average PASI score was observed among patient groups stratified based on the number of minor alleles of CD6 and ALCAM polymorphisms, indicating a potential influence of these genetic variations on disease severity.

These findings suggest that polymorphisms in CD6 and ALCAM genes may modulate both the susceptibility to PsV and its clinical outcomes. Understanding the genetic factors contributing to psoriasis pathogenesis and severity could aid in risk assessment and personalized treatment strategies for patients with this condition. Further research may elucidate the precise mechanisms by which these genetic variations affect psoriasis development and progression.

Reference
Wagner M, Sobczyński M, Wiśniewski A, Matusiak Ł, Kuśnierczyk P, Jasek M. Polymorphisms in the CD6-ALCAM axis may modulate psoriasis risk and outcomes. Hum Immunol. Published online April 5, 2024. doi:10.1016/j.humimm.2024.110797